Navigation Links
Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
Date:7/26/2017

MONTREAL, July 26th, 2017 /PRNewswire/ - Caprion Biosciences Inc., a world leading specialty CRO announced the publication of a novel study identifying host blood proteins predictive of early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ProteoCarta™, a mass spectrometry (MS) and multiple reaction monitoring (MRM-MS) platform.

Caprion Biosciences Inc. (CNW Group/Caprion Biosciences)
Caprion Biosciences Inc. (CNW Group/Caprion Biosciences)

The new data, recently published in EbioMedicine, expands and strengthens Caprion's existing portfolio of biomarkers assays for predicting and monitoring of active TB, supporting clients who are developing TB therapeutics and diagnostics. "These findings are very significant and could impact the way we approach treatment, providing a solid basis to accelerate the development of predictive testing" said Eustache Paramithiotis, Vice-President of Discovery at Caprion, who led the study in collaboration Charles Bark, MD and W. Henry Boom, MD from Case Western Reserve University.

In this proteomic study, host proteins expressed differentially between patients uninfected and individuals exposed to M. tuberculosis through contact with family members, which were followed over a period of 12 months. Caprion's bioinformatic analysis determined multiple biomarker signatures correlating with subsequent development of an immune response recognizing Mtb. These biomarker signatures may demonstrate individuals recently infected by Mtb at high risk for developing active tuberculosis (TB).  

About Latent M. Tuberculosis Infection (LTBI) and Active TB 
LTBI is a state of persistent immune response resulting from Mtb infection but without evidence of clinically active TB. Current immune-based tests for Mtb infection (LTBI) cannot distinguish recent from remote Mtb infection.  Individuals with recent Mtb infection are at highest risk for developing disease, i.e. TB.  These tests also cannot distinguish LTBI from TB. Worldwide, approximately one-third of the population is latently infected with Mtb, meaning that they do not display any symptoms, chest radiographic abnormalities, or other findings of active TB. Approximately 10% of people with LTBI will develop active TB and are the primary source of TB spreading. Their identification is critical to efforts aimed at controlling TB.

About Caprion Biosciences, Inc.   
Founded in 2000, Caprion is a leading specialty CRO laboratory providing an integrated platform in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free MS for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and in Gosselies, Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP.

For more information, www.caprion.com


'/>"/>
SOURCE Caprion Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
2. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
3. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
4. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
5. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
6. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
7. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
8. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
9. TOMA Biosciences Releases the COMPASS Tumor Profiling System
10. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
11. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
(Date:7/31/2020)... MIAMI (PRWEB) , ... July 29, 2020 , ... ... nearly 200 of the top radiation centers in 16 countries, has reached its ... years, SDX® is now in routine use at top universities including University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... of Technology (MIT) has expanded the company’s exclusive license to include clinical ... the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ ...
Breaking Biology Technology:
(Date:6/11/2020)... ... 08, 2020 , ... Cryo-Cell International’s announcement comes on the ... in the medical field. The face masks will be distributed nationwide to obstetrical ... day to provide healthcare to pregnant women. The delivery of masks is scheduled ...
(Date:6/5/2020)... , ... June 04, 2020 , ... “Although we are ... and well-being of our attendees, staff, and the public. We remain committed to ... safe ways to collaborate virtually,” said Julie Sutcliffe, President of WMIS. ...
(Date:5/30/2020)... , ... May 29, 2020 , ... ... digital transformation for enterprises globally, has collaborated with EchoNous Inc. to develop the ... It can measure systolic heart function, which has been clinically tested versus expert ...
Breaking Biology News(10 mins):